Claims
- 1. A method for the alleviation of inflammation without causing any noticeable systemic effect which comprises administering to a host a antiinflammatory-effective amount of a dexamethasone derivative of the formula ##STR3## in which R represents an alkyl radical comprising a number of carbon atoms between 4 and 9 or a para-fluoro-phenyl radical.
- 2. The method of claim 1, which comprises administering dexamethasone 21-thiopivalate as dexamethasone derivative.
- 3. The method of claim 1, which comprises administering dexamethasone 21-thiopentanoate as dexamethasone derivative.
- 4. The method of claim 1, which comprises administering dexamethasone 21-thiol-2-methyl-butanoate as dexamethasone derivative.
- 5. The method of claim 1, which comprises administering dexamethasone 21-thiol-3-methyl-butanoate as dexamethasone derivative.
- 6. The method of claim 1, which comprises administering dexamethasone 21-thiohexanoate as dexamethasone derivative.
- 7. The method of claim 1, which comprises administering dexamethasone 21-thiol-4-methyl-pentanoate as dexamethasone derivative.
- 8. The method of claim 1, which comprises administering dexamethasone 21-thiol-3,3-dimethyl-butanoate as dexamethasone derivative.
- 9. The method of claim 1, which comprises administering dexamethasone 21-thiol-2-ethyl-butanoate as dexamethasone derivative.
- 10. The method of claim 1, which comprises administering dexamethasone 21-thiooctanoate as dexamethasone derivative.
- 11. The method of claim 1, which comprises administering dexamethasone 21-thiol-2-ethyl-hexanoate as dexamethasone derivative.
- 12. The method of claim 1, which comprises administering dexamethasone 21-thiononanoate as dexamethasone derivative.
- 13. The method of claim 1, which comprises administering dexamethasone 21-thiodecanoate as dexamethasone derivative.
- 14. The method of claim 1, which comprises administering dexamethasone 21-p-fluorothiobenzoate as dexamethasone derivative.
- 15. A pharmaceutical composition comprising 0,005 to 5% of a dexamethasone derivative of the formula ##STR4## in which R represents an alkylradical having from 4 to 9 carbon atoms or the para-fluoro phenyl radical, and an acceptable pharmaceutical carrier, this composition being presented in the form of a lotion, a spray, ear, ophtalmic or nasal drops, a mouthwash, injectable solutions, pastilles, ointments, creams, oral or rectal suspensions, and the like.
- 16. The pharmaceutical composition of claim 15 for oral or parenteral administration comprising 1% of dexamethasone derivative.
- 17. The pharmaceutical composition of claim 15 for topical application, comprising 0,01% of dexamethasone derivative.
- 18. The 21-p-fluoro-thio-benzoate of dexamethasone.
Priority Claims (1)
Number |
Date |
Country |
Kind |
73 19734 |
May 1973 |
FRX |
|
CROSS REFERENCE
The present application is a continuation in part application of application Ser. No. 473,388, filed May 28, 1974, now U.S. Pat. No. 4,014,909.
US Referenced Citations (3)
Foreign Referenced Citations (2)
Number |
Date |
Country |
1187M |
Mar 1962 |
FRX |
2070077 |
Oct 1971 |
FRX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
473388 |
May 1974 |
|